Montelukast Protects Against Renal Damage Due to Cadmium Toxicity: In vivo and In vitro Experiments

Background: The protective effects of Montelukast (Mont), as an anti-inflammatory drug, against cadmium-induced kidney cell damage have already been studied and identified. Since the significant part cadmium nephrotoxicity is caused by oxidative stress, this in vivo vitro study was conducted to investigate possible role antioxidant properties protection. Methods: In section, 42 rats were treated seven groups six follows: Control; Cadmium Chloride (CdCl2) control; CdCl2 plus treatment; with pre-treatment; Vitamin E treatment. human embryonic cells (HEK293) CdCl2; Montelukast; Combined E; E. Results: Montelukast, both treatment pretreatment forms, reduced serum urea, creatinine, potassium levels compared group, vivo. Similar vitamin E, pre-treatment associated a decrease Nitric Oxide (NO) Total Antioxidant Capacity (TAC) renal tissue, increase Glutathione Peroxidase (GPX) activity those group. section study, significantly Malondialdehyde (MDA) NO while TAC level, Superoxide Dismutase (SOD), GPX increased significantly. Conclusion: Overall, appear play prominent preventing toxicity due exposure.